Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Leases (2019 - 2023)

Historic Current Leases for Alaunos Therapeutics (TCRT) over the last 5 years, with Q3 2023 value amounting to $307000.0.

  • Alaunos Therapeutics' Current Leases fell 4335.79% to $307000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $307000.0, marking a year-over-year decrease of 4335.79%. This contributed to the annual value of $558000.0 for FY2022, which is 2345.68% down from last year.
  • As of Q3 2023, Alaunos Therapeutics' Current Leases stood at $307000.0, which was down 4335.79% from $339000.0 recorded in Q2 2023.
  • Alaunos Therapeutics' Current Leases' 5-year high stood at $866000.0 during Q3 2020, with a 5-year trough of $307000.0 in Q3 2023.
  • In the last 5 years, Alaunos Therapeutics' Current Leases had a median value of $693500.0 in 2019 and averaged $660333.3.
  • In the last 5 years, Alaunos Therapeutics' Current Leases soared by 2857.14% in 2020 and then tumbled by 4335.79% in 2023.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Current Leases stood at $677000.0 in 2019, then increased by 20.97% to $819000.0 in 2020, then dropped by 10.99% to $729000.0 in 2021, then fell by 23.46% to $558000.0 in 2022, then crashed by 44.98% to $307000.0 in 2023.
  • Its Current Leases was $307000.0 in Q3 2023, compared to $339000.0 in Q2 2023 and $575000.0 in Q1 2023.